A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers — HERIZON-BTC-01  

HER2-amplified Biliary Tract Cancers Clinical Trial

Official title: A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers

Status Active, not recruiting

Clinical Trial Summary

This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Biliary Tract Neoplasms
• HER2-amplified Biliary Tract Cancers

• NCT number: NCT04466891
• Study type: Interventional
• Source: Jazz Pharmaceuticals
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 1, 2020
• Completion date: October 31, 2024